Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer’s disease

Key Points

• Investigate the effectiveness of monoclonal antibodies targeting amyloid-beta in treating cognitive decline associated with Alzheimer's disease.
• Conducting a systematic review and meta-analysis
• Selecting studies that involve amyloid-beta-targeting monoclonal antibodies
• Evaluating outcomes related to cognitive function in mild cognitive impairment and mild dementia populations
• Potential improvements in cognitive function observed
• Clearer understanding of treatment efficacy and safety
• Identification of appropriate dosage and administration strategies